<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077449</url>
  </required_header>
  <id_info>
    <org_study_id>XZP-3287-3001</org_study_id>
    <nct_id>NCT05077449</nct_id>
  </id_info>
  <brief_title>A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanzhu Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanzhu Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in&#xD;
      combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR&#xD;
      positive and Her2 negative recurrent/metastatic breast cancer and have received prior&#xD;
      endocrine therapy are eligible for study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-assessed progression free survival (PFS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BICR-assessed progression free survival (PFS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate(OSR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Up to approximately 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration [Tmax]</measure>
    <time_frame>Up to approximately 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time-concentration Curve [AUC]</measure>
    <time_frame>Up to approximately 4 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>EORTC QLQ-C30 scale</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EORTC QLQ-BR23 scale</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D-5L scale</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma ctDNA</measure>
    <time_frame>Up to approximately 5 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>XZP-3287+Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Fulvestrant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XZP-3287+Fulvestrant</intervention_name>
    <description>XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease</description>
    <arm_group_label>XZP-3287+Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Fulvestrant</intervention_name>
    <description>Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease</description>
    <arm_group_label>Placebo + Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients aged ≥18 years and ≤75 years old;&#xD;
&#xD;
          2. Patient is in the menopausal state；&#xD;
&#xD;
          3. Pathologically-confirmed HR positive and Her2 negative Breast Cancer;&#xD;
&#xD;
          4. Locally advanced stage, recurrence or metastasis breast cancer; 4.1 Disease&#xD;
             progression after previous endocrine therapy； 4.2 One previous line of chemotherapy&#xD;
             for advanced/metastatic disease is allowed in addition to endocrine therapy;&#xD;
&#xD;
          5. At least one measurable lesion (based on RECIST v1.1) or only bone metastases;&#xD;
&#xD;
          6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;&#xD;
&#xD;
          7. Adequate organ and marrow function;&#xD;
&#xD;
          8. Patient of childbearing age must undergo a serum pregnancy test within 14 days before&#xD;
             randomization, and the result is negative; patient is willing to use a medically&#xD;
             approved high-efficiency contraceptive method during the study period and within 6&#xD;
             months after the last study drug treatment;&#xD;
&#xD;
          9. Patient with acute toxic reactions caused by previous anti-tumor treatments or&#xD;
             surgical operations were alleviated to grade 0 to 1 (NCI-CTCAE v5.0), or to the level&#xD;
             specified by the enrollment criteria;&#xD;
&#xD;
         10. Patient has signed informed consent before any trial related activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with visceral crisis, inflammatory breast cancer, or brain metastases, except&#xD;
             for patient with stable brain metastases;&#xD;
&#xD;
          2. Patient had clinically significant pleural effusions, ascites effusions, or&#xD;
             pericardial effusions in the 4 weeks before enrollment;&#xD;
&#xD;
          3. Patient who received prior treatment with mTOR inhibitors, CDK4/6 inhibitors or&#xD;
             fulvestrant;&#xD;
&#xD;
          4. Participation in a prior treatment of major surgery, chemotherapy, radiotherapy, and&#xD;
             any anti-tumor treatment within 14 days before enrollment；&#xD;
&#xD;
          5. Patient who participated in other clinical trials within 14 days before enrollment or&#xD;
             within 5 half-lives of the trial drug, whichever is longer;&#xD;
&#xD;
          6. Patient used CYP3A4 potent inhibitors or potent inducers within 14 days before&#xD;
             enrollment or within 5 half-lives of the drug, whichever is longer;&#xD;
&#xD;
          7. Patient who used bisphosphonates or RANKL inhibitors within 7 days before enrollment,&#xD;
             patient who have started treatment during the study should not change the method of&#xD;
             use;&#xD;
&#xD;
          8. Any other malignant tumor has been diagnosed within 3 years before randomization;&#xD;
&#xD;
          9. Patient is in the active stage of HBV, HCV or co-infected with HBV, HCV, or Patient&#xD;
             with positive HIV antibody;&#xD;
&#xD;
         10. Patient with severe infection within 4 weeks before enrollment, or unexplained fever&gt;&#xD;
             38.5℃ during screening/before enrollment;&#xD;
&#xD;
         11. Patient with heart function impaired or clinically significant heart disease within 6&#xD;
             months before enrollment;&#xD;
&#xD;
         12. Cerebrovascular accident occurred within 6 months before enrollment, including history&#xD;
             of transient ischemic attack or stroke; symptomatic pulmonary embolism;&#xD;
&#xD;
         13. Inability to swallow, intestinal obstruction or other factors that affect the taking&#xD;
             and absorption of the drug;&#xD;
&#xD;
         14. Patient with a known hypersensitivity to any of the excipients in this study;&#xD;
&#xD;
         15. A prior history of autologous or allogeneic hematopoietic stem cell transplantation;&#xD;
&#xD;
         16. A prior history of psychotropic drug abuse or drug use;&#xD;
&#xD;
         17. Pregnant or breastfeeding;&#xD;
&#xD;
         18. The researchers considered that there were some cases that were not suitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Jiang</last_name>
    <phone>13811602879</phone>
    <email>jianghai@xuanzhupharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Binghe Xu</last_name>
    </contact>
    <contact_backup>
      <phone>(+86)(10)(87788826)</phone>
      <email>xubinghe@csco.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XZP-3287</keyword>
  <keyword>HR positive and Her2 negative</keyword>
  <keyword>recurrent/metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

